التفاصيل البيبلوغرافية
| العنوان: |
PCN157 COST-EFFECTIVENESS ANALYSIS OF NIVOLUMAB + IPILIMUMAB VERSUS SUNITINIB IN THE FIRST-LINE TREATMENT OF ADVANCED OR METASTATIC INTERMEDIATE- OR POOR-RISK RENAL CELL CARCINOMA IN SPAIN. |
| المؤلفون: |
Polanco Sánchez, C.1 (AUTHOR), Pérez-Alcántara, F.2 (AUTHOR), May, J.3 (AUTHOR), Gooden, K.M.4 (AUTHOR), Malcolm, B.5 (AUTHOR), Arranz, J.A.6 (AUTHOR), Duran, I.7 (AUTHOR), García-Donas, J.8 (AUTHOR), Gallardo, E.9 (AUTHOR), Láinez, N.10 (AUTHOR), Maroto, P.11 (AUTHOR), Valderrama, B.P.12 (AUTHOR), Puente, J.13 (AUTHOR), Vázquez, S.14 (AUTHOR), Van de Wetering, G.15 (AUTHOR), Smith van Carroll, L.E.16 (AUTHOR) |
| المصدر: |
Value in Health. 2019 Supplement 3, Vol. 22, pS466-S466. 1p. |
| مصطلحات موضوعية: |
*IPILIMUMAB, *RENAL cell carcinoma, *COST effectiveness, *TERMINATION of treatment |
| مصطلحات جغرافية: |
SPAIN |
| مستخلص: |
Nivolumab plus ipilimumab (nivolumab+ipilimumab) is the first immuno-oncology combination that has shown significant, long-term overall survival (OS) benefit for the first-line treatment of adult patients with intermediate- or poor-risk advanced renal cell carcinoma (1L RCC) compared with standard of care (sunitinib). Outcomes of interest were total costs, life years (LYs), quality-adjusted life-years (QALYs), and the incremental cost-utility ratio (ICUR). Based on the DSA, the key ICUR drivers were the proportion of patients receiving treatment after sunitinib and the maximum treatment duration for nivolumab+ipilimumab. [Extracted from the article] |
| قاعدة البيانات: |
Academic Search Index |
Full Text Finder